Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Apr 17;19(1):47.
doi: 10.1186/s12933-020-01022-7.

Report from the 5th cardiovascular outcome trial (CVOT) summit

Oliver Schnell  1 , Eberhard Standl  2 , Xavier Cos  3 , Hiddo Jl Heerspink  4   5 , Baruch Itzhak  6 , Nebojsa Lalic  7 , Michael Nauck  8 , Antonio Ceriello  9
Affiliations
Editorial

Report from the 5th cardiovascular outcome trial (CVOT) summit

Oliver Schnell et al. Cardiovasc Diabetol. .

Abstract

The 5th Cardiovascular Outcome Trial (CVOT) Summit was held in Munich on October 24th-25th, 2019. As in previous years, this summit served as a reference meeting for in-depth discussions on the topic of recently completed and presented CVOTs. This year, focus was placed on the CVOTs CAROLINA, CREDENCE, DAPA-HF, REWIND, and PIONEER-6. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussions evolved from CVOTs to additional therapy options for heart failure (ARNI), knowledge gained for the treatment and prevention of heart failure and diabetic kidney disease in populations with and without diabetes, particularly using SGLT-2 inhibitors and GLP-1 receptor agonists. Furthermore, the ever increasing impact of CVOTs and substances tested for primary prevention and primary care was discussed. The 6th Cardiovascular Outcome Trial Summit will be held in Munich on October 29th-30th, 2020 (https://www.cvot.org).

Keywords: CAROLINA; CREDENCE; CVOT; Cardiovascular risk; DAPA-HF; Diabetes; GLP-1 receptor agonist; PIONEER-6; REWIND; SGLT-2 inhibitor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843. - DOI - PubMed
    1. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovascular diabetology. 2018;17(1):83. doi: 10.1186/s12933-018-0728-6. - DOI - PMC - PubMed
    1. Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018. doi: 10.1038/nrdp.2015.18. - DOI - PMC - PubMed
    1. Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302–308. doi: 10.1681/ASN.2012070718. - DOI - PMC - PubMed
    1. Guidance for industry diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. In: FDA, eds, 2008.

MeSH terms

Substances